Rimcazole

Rimcazole is a sigma receptor antagonist, which was developed as an antipsychotic, but was later discovered to have antidepressant effects. It is structurally related to the benzamide antipsychotics, although its mechanism of action is distinct.

History

Rimcazole was first synthesized in the 1980s by the pharmaceutical company Janssen Pharmaceutica, with the intention of developing a new antipsychotic drug. However, clinical trials showed that it was not effective for this purpose. Later research discovered that rimcazole has antidepressant effects, and it has been studied for potential use in the treatment of depression and drug addiction.

Pharmacology

Rimcazole acts as an antagonist at the sigma receptor, a type of protein that is found in the brain and other parts of the body. Sigma receptors are involved in many different physiological processes, and drugs that affect these receptors can have a wide range of effects.

Rimcazole is structurally related to the benzamide antipsychotics, a class of drugs that includes sulpiride and amisulpride. However, unlike these drugs, rimcazole does not act at dopamine receptors.

Clinical use

Although rimcazole was initially developed as an antipsychotic, it is not currently used for this purpose. Instead, it has been studied for potential use in the treatment of depression and drug addiction.

In animal studies, rimcazole has been shown to have antidepressant effects. It is thought to work by blocking the effects of stress hormones on the brain, which can contribute to depression.

Rimcazole has also been studied for its potential to treat drug addiction. It has been shown to reduce the rewarding effects of cocaine in animals, suggesting that it could be used to help people stop using this drug.

See also

• Sigma receptor
• Antipsychotic
• Antidepressant
• Benzamide

• 
  Rimcazole